MENS net incomeFY2025-$4.67M
MENS net income was -$4.67M for fiscal 2025 (ended Dec 31, 2025), compared with -$3.02M in fiscal 2024.
Jyong Biotech Ltd. (MENS) financials
For fiscal 2025 (ended Dec 31, 2025), Jyong Biotech Ltd. reported -$4.67M of net income.
- Net income, FY2025
- -$4.67M
- EPS, diluted, FY2025
- -$0.06
- Cash
- $1.18M
- Total debt
- $2.12M
- Market cap
- $140.7M
FY2023FY2025
MENS revenue and earnings growth
MENS EPSFY2025-$0.06
MENS diluted EPS was -$0.06 for fiscal 2025 (ended Dec 31, 2025), compared with -$0.04 in fiscal 2024.
Income statement
| Line item | Dec 31, 2025 | Dec 31, 2024 | Dec 31, 2023 |
|---|---|---|---|
| Research and development | $813.0K | $927.0K | $1.07M |
| Selling, general and admin | $1.75M | $1.08M | $1.68M |
| Operating income | -$2.61M | -$2.06M | -$2.80M |
| Interest expense | $2.54M | $1.03M | $757.0K |
| Pre-tax income | -$4.67M | -$3.02M | -$4.40M |
| Net income | -$4.67M | -$3.02M | -$4.40M |
| EPS, basic | -$0.06 | -$0.04 | -$0.06 |
| EPS, diluted | -$0.06 | -$0.04 | -$0.06 |
| Diluted shares | 73.0M | 71.6M | 71.6M |
Balance sheet
| Line item | Dec 31, 2025 | Dec 31, 2024 | Dec 31, 2023 |
|---|---|---|---|
| Cash and equivalents | $1.18M | $101.0K | $1.74M |
| Current assets | $15.54M | $206.0K | - |
| Total assets | $20.78M | $6.37M | - |
| Current liabilities | $34.81M | $12.13M | - |
| Short-term debt | $15.34M | - | - |
| Total debt | $2.12M | - | - |
| Total liabilities | $45.68M | $42.88M | - |
| Shareholders' equity | -$24.91M | -$36.52M | -$34.07M |
Cash flow
| Line item | Dec 31, 2025 | Dec 31, 2024 | Dec 31, 2023 |
|---|---|---|---|
| Operating cash flow | -$3.04M | -$3.62M | -$2.60M |
| Investing cash flow | -$13.51M | - | $95.0K |
| Financing cash flow | $17.63M | $1.99M | $2.03M |
| Depreciation and amortization | $100.0K | $120.0K | $127.0K |
Key ratios
Source: XBRL data Jyong Biotech Ltd. files with the SEC, latest filing dated May 15, 2026 (see filings on SEC EDGAR). Provided for information only, not investment advice. Check the filing before relying on a number.
Per-share figures are as filed. The filings show no stock split in these periods.
EPS growth is left out where the share count moved enough to suggest a split the filings do not show. Growth rates need a positive starting figure. CAGR is compound annual growth between fiscal years. The CSV holds every period on file, in full figures, from the same SEC filings.
Foreign private issuers file annual reports with the SEC, so there are no quarterly statements here.
MENS peers
| Company | Revenue | Growth | Net income | Net margin | Market cap |
|---|---|---|---|---|---|
| MENS | - | - | -$4.67M | - | $140.7M |
| LLY | $86.46B | +45.5% | $27.58B | 31.9% | $1.33T |
| JNJ | $99.33B | +7.8% | $16.09B | 16.2% | $679.13B |
| ABBV | $66.01B | +10.7% | $10.34B | 15.7% | $518.44B |
| MRK | $67.38B | +4.9% | $2.45B | 3.6% | $366.73B |
| NVS | $54.53B | +8.4% | $13.98B | 25.6% | $312.35B |
| AZN | $58.74B | +8.6% | $10.22B | 17.4% | $293.69B |
| ABT | $48.23B | +10.0% | $4.70B | 9.7% | $191.40B |
| NVO | DKK 309.06B | +6.4% | DKK 102.43B | 33.1% | $183.23B |
MENS FAQ
5 questionsIs MENS profitable?
No. Jyong Biotech Ltd. reported a net loss of $4.67M for fiscal 2025 (ended Dec 31, 2025).How much cash and debt does MENS have?
Jyong Biotech Ltd. reported $1.18M in cash and cash equivalents and $2.12M of debt on its most recent balance sheet in SEC filings.What is MENS earnings per share?
Diluted earnings per share were -$0.06 for fiscal 2025 (ended Dec 31, 2025), from SEC filings, restated for any stock split those filings show.When did MENS last report financial results?
The latest statements here come from Jyong Biotech Ltd.'s 20-F filed on May 15, 2026, covering the period ended Dec 31, 2025.Where does this MENS financial data come from?
Quantisnow builds these statements from the structured XBRL data Jyong Biotech Ltd. files with the SEC. It is provided for information only and is not investment advice.